Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis.|https://dx.doi.org/10.1097/MD.0000000000039213
The impact of 30-day antecedent antibiotic exposure on C. difficile ribotype patterns and the relationship with clinical outcomes: A single center study.|https://dx.doi.org/10.1016/j.anaerobe.2024.102894
Comparative effectiveness of vancomycin and metronidazole on event-free survival after initial infection in patients with Clostridioides difficile - a German multicentre cohort study (IBIS).|https://dx.doi.org/10.1016/j.cmi.2024.08.003
Symbiotic biofilms formed by Clostridioides difficile and bacteroides thetaiotaomicron in the presence of vancomycin.|https://dx.doi.org/10.1080/19490976.2024.2390133
Is advanced age still a risk factor for recurrence of C. difficile infection in the era of new treatments?|https://dx.doi.org/10.1093/ageing/afae182
Microbiome modification for personalized treatment of dysbiotic diseases.|https://dx.doi.org/10.1016/j.chom.2024.07.023
Use of frozen native feces for fecal microbiota transplantation in recurrent Clostridioides difficile infection: a simple way to improve the efficiency of donor feces preparation.|https://dx.doi.org/10.1128/aac.00734-24
Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA®) for Preventing Recurrent Clostridioides difficile Infection.|https://dx.doi.org/10.1093/infdis/jiae418
Reduction of Antibiotic-Associated Conditions After Tympanostomy Tube Placement in Children.|https://dx.doi.org/10.1002/lary.31717
The end of toxoid vaccine development for preventing Clostridioides difficile infections?|https://dx.doi.org/10.1093/cid/ciae412
From Hemorrhage to Diarrhea: The Comprehensive Clinical Journey of a Patient With Pseudomembranous Colitis.|https://dx.doi.org/10.7759/cureus.65176
PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1093/cid/ciae437
CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.|https://dx.doi.org/10.1093/cid/ciae410
Targeting the Microbiome to Improve Human Health with the Approach of Personalized Medicine: Latest Aspects and Current Updates.|https://dx.doi.org/10.1016/j.clnesp.2024.08.005
Fecal Microbiota, Live-jslm (RBL; REBYOTA®) for Prevention of Recurrent Clostridioides difficile Infection: What Gastroenterology Nurses Need to Know.|https://dx.doi.org/10.1097/SGA.0000000000000847
Gut microbiome and plasma lipidome analysis reveals a specific impact of Clostridioides difficile infection on intestinal bacterial communities and sterol metabolism.|https://dx.doi.org/10.1128/mbio.01347-24
Role of glycogen metabolism in Clostridioides difficile virulence.|https://dx.doi.org/10.1128/msphere.00310-24
How to develop a Controlled Human Infection Model for Clostridioides difficile.|https://dx.doi.org/10.1016/j.cmi.2024.08.025
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.|https://dx.doi.org/10.1007/s40121-024-01036-8
Validation of Lyophilized Human Fecal Microbiota for the Treatment of Clostridioides difficile Infection: A Pilot Study with Pharmacoeconomic Analysis of a Middle-Income Country-Promicrobioma Project.|https://dx.doi.org/10.3390/microorganisms12081741
Retrospective, Propensity Score Matched Study Examining Relationship between Frailty and Clostridioides difficile Infection in a National Cohort of United States Veterans.|https://dx.doi.org/10.1016/j.ajic.2024.08.020
Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics.|https://dx.doi.org/10.1080/19490976.2024.2393766
